Novartis AG (NVSEF)
OTCMKTS · Delayed Price · Currency is USD
127.81
0.00 (0.00%)
Oct 27, 2025, 8:00 PM EDT
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$742,880
Profits / Employee
$189,674
Market Cap
239.27B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| LogicMark | 32 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Novartis AG News
- 22 hours ago - Novartis completes acquisition of Tourmaline Bio - GlobeNewsWire
- 1 day ago - Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue - Invezz
- 1 day ago - Novartis looking to add more medicines to direct to patient platform, CEO says - Reuters
- 1 day ago - Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done' - CNBC
- 1 day ago - Novartis Posts Higher Net Profit as Key Drugs Lift Sales - WSJ
- 1 day ago - Novartis announces expiration of Tourmaline Bio tender offer - GlobeNewsWire
- 1 day ago - Novartis Q3 operating income up 6% on new drug sales - Reuters
- 1 day ago - Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance - GlobeNewsWire